Floatz logo

Glycosylated Recombinant Human Interleukin-7

Stage III Ureter Cancer AJCC v8

National Cancer Institute (NCI)Phase 2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

16 Active assets in the Stage III Ureter Cancer AJCC v8 cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
University Health Network, Toronto
Phase 3BB
ENFORTUMAB VEDOTIN (fully human monoclonal antibody conjugated to a cytotoxic agent monomethyl auristatin E (MMAE) targeting nectin-4)
Fred Hutchinson Cancer Center
Phase 2BB
Carboplatin
University Health Network, Toronto
Phase 2BB
Vinflunine
Dr Anders Ullén
Phase 2BB
Pembrolizumab
Fred Hutchinson Cancer Center
Phase 2BB

View all 33 →

Same molecule, other indications

Glycosylated Recombinant Human Interleukin-7 is also rated in:

hypogonadismDormant
CCC
Indicative ·
52 / 100
View asset →
metastatic prostate carcinomaDormant
CCC
Indicative ·
52 / 100
View asset →
prostate cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →